Cytokinetics rises as lead drug succeeds in late-stage trial

2025-05-13 20:49

Shares of Cytokinetics (NASDAQ:CYTK) traded higher in the premarket on Tuesday after the company said that its lead asset, aficamten, reached the main goal in a Phase 3 trial for patients with a heart muscle disorder called obstructive hypertrophic cardiomyopathy (HCM).
Citing topline data from its MAPLE-HCM trial, Cytokinetics (NASDAQ:CYTK) said that the cardiac myosin inhibitor hit the study’s main goal, indicating a statistically significant improvement in peak oxygen uptake (pVO2) over 24 weeks from baseline.
The 175-patient trial was designed to evaluate aficamten against the standard of care beta-blocker metoprolol as a single agent in symptomatic obstructive HCM.
As for safety and tolerability, the company said that its small-molecule drug indicated favorable data compared to metoprolol.
The readout comes as the drug is currently under review by the FDA with a target action date of Dec. 26 for obstructive HCM.

More on Cytokinetics